MedTrace Logo

Purinergic Signaling and the Postmenopausal Heart

NCT06015776 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 500

Last updated 2026-03-20

No results posted yet for this study

Summary

There is an increased risk of diastolic heart failure in post menopausal women. Estrogen plays a positive role in regulating molecular pathways in heart remodeling. Such pathways may work through purinergic signaling and its downstream effects on the heart's mitochondrial metabolism and angiogenic response to stress. Loss of estrogen functionality in post menopausal women may account for the increased risk of diastolic heart failure. The investigators will explore said pathways using cardiac tissue obtained from patients undergoing cardiac surgery.

Conditions

Interventions

OTHER

Gender

Differences between men and women will be observed

Sponsors & Collaborators

Principal Investigators

  • Robina Matyal, MD · Beth Israel Deaconess Medical Center, Professor of Anesthesia

  • Simon Robson, MD, PhD · Beth Israel Deaconess Medical Center,Vice Chair Research

Eligibility

Min Age
30 Years
Max Age
88 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-07-01
Primary Completion
2030-06-30
Completion
2030-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06015776 on ClinicalTrials.gov